Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Policy / Regulatory

Shanghai Issues Legal Guidebook for Innovative Drug Marketing

Fineline Cube Feb 22, 2025

The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...

Policy / Regulatory

China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation

Fineline Cube Feb 22, 2025

The Chinese government has released a set of opinions detailing the establishment of a new...

Company Drug

Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma

Fineline Cube Feb 21, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co.,...

Company Drug

GSK’s Nucala Receives NMPA Review for COPD Treatment

Fineline Cube Feb 21, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE

Fineline Cube Feb 21, 2025

According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...

Company

Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY

Fineline Cube Feb 21, 2025

Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75...

Company Deals Medical Device

Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech

Fineline Cube Feb 21, 2025

Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and...

Company Deals

Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies

Fineline Cube Feb 21, 2025

Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance...

Company Drug

Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study

Fineline Cube Feb 21, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...

Company Drug

Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval

Fineline Cube Feb 21, 2025

China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to...

Company Deals

Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development

Fineline Cube Feb 21, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...

Company Drug

Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis

Fineline Cube Feb 21, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...

Company Deals

FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included

Fineline Cube Feb 21, 2025

US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...

Company Deals

Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem

Fineline Cube Feb 21, 2025

China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with...

Company Drug

Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931

Fineline Cube Feb 21, 2025

German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...

Company Drug

Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review

Fineline Cube Feb 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Policy / Regulatory

Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025

Fineline Cube Feb 20, 2025

In a significant move to bolster foreign investment and enhance the country’s economic openness, the...

Company Deals

Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research

Fineline Cube Feb 20, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China

Fineline Cube Feb 20, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the...

Company Drug

Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease

Fineline Cube Feb 20, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that its gene therapy subsidiary AskBio Inc. has...

Posts pagination

1 … 210 211 212 … 667

Recent updates

  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.